Organization | Immodulon Therapeutics Ltd

Immodulon Therapeutics Ltd Report issue

For profit Phase 2 Phase 3

Founded: London United Kingdom (2007)

Organization Overview

First Clinical Trial

2010

NCT01308762

First Marketed Drug

None

First NDA Approval

None

Last Known Activity

2021

Timeline

NOW

Now

Alternative names

Immodulon Therapeutics Ltd

Active Ingredients

Drugs in Phase 3 Trials (1)

Inactivated Mycobacterium obuense (8 trials)

Drugs in Phase 2 Trials (13)

atezolizumab (Tecentriq) (1 trial)

capecitabine (xeloda) (1 trial)

cetuximab (erbitux) (1 trial)

cyclophosphamide (cytoxan) (1 trial)

fluorouracil (efudex) (1 trial)

gemcitabine (gemzar) (2 trials)

ipilimumab (yervoy) (2 trials)

irinotecan (Camptosar) (1 trial)

leucovorin (1 trial)

nivolumab (opdivo) (2 trials)

oxaliplatin (eloxatin) (1 trial)

paclitaxel (taxol) (1 trial)

pembrolizumab (keytruda) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)

Colorectal Neoplasms (Phase 2)

Infections (Phase 3)

Melanoma (Phase 2)

Necrosis (Phase 2)

Neoplasm Metastasis (Phase 2)

Pancreatic Neoplasms (Phase 2)

Overview

Highest Phase: Phase 3
# of Trials: 9
# of Trial APIs: 14